Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis

• Published in: Indian journal of gastroenterology 2022-10, Vol.41 (5), p.446-455
• Main Authors: Kumar, Peeyush, Vuyyuru, Sudheer K., Kante, Bhaskar, Kedia, Saurabh, Sahu, Pabitra, Ranjan, Mukesh Kumar, Mundhra, Sandeep, Golla, Rithvik, Kumar, Mukesh, Virmani, Shubi, Gupta, Anvita, Yadav, Nidhi, Makharia, Govind, Ahuja, Vineet
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Biosimilar Pharmaceuticals - adverse effects; Chronic Disease; Colitis, Ulcerative - drug therapy; Crohn Disease - drug therapy; Gastroenterology; Gastrointestinal Agents - adverse effects; Hepatology; Humans; Inflammatory Bowel Diseases - drug therapy; Infliximab - adverse effects; Medicine; Medicine & Public Health; Original Article; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor Inhibitors
• ISSN: 0254-8860; 0975-0711
• DOI: 10.1007/s12664-022-01252-5

Background Anti-tumor necrosis factor (anti-TNF) monoclonal antibody, infliximab, is the primary therapeutic modality for patients with Crohn’s disease (CD) and ulcerative colitis (UC), refractory to conventional therapy. Biosimilars of infliximab have been shown to have equivalent efficacy to originator infliximab. We compared the safety and efficacy of infliximab biosimilar with the originator in Indian patients with inflammatory bowel disease (IBD). Methods Patients with IBD treated with either originator or biosimilar infliximab from January 2005 to October 2020 were included in this retrospective analysis. The safety and efficacy of originator or biosimilar infliximab in inducing and maintaining clinical remission at weeks 14 and 52 for CD and UC were evaluated. Disease activity was estimated at baseline, after induction therapy, after 1 year of treatment, and during 12 months of follow-up. Results In all, 137 patients (82 CD; 55 UC) were included, of whom 102 were on originator, and 35 patients received biosimilar. In biosimilar group, clinical response and remission rates at weeks 14 and 52 were 84.2%, 58% and 68.4%, 52.6% in CD and 81.2%, 56.2% and 68.7%, 62.5% in UC patients, respectively. Among patients who were on originator, clinical response and remission rates at weeks 14 and 52 were 79.4%, 46% and 57.1%, 43% in CD and 72%, 64.1% and 66.7%, 56.4% in UC patients, respectively. Thirty-three (24.1%) patients experienced adverse events; eighteen developed tuberculosis (TB), of whom 17 received originator and one patient received biosimilar. Conclusions Infliximab biosimilar is comparable to originator infliximab in terms of safety profile and its efficacy in inducing and maintaining remission in patients with IBD.